Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
Ziyu LiYongning JiaHonglin ZhuXiaofang XingFei PangFei ShanShuangxi LiDanhua WangFangping ZhaoTonghui MaSizhen WangJia Fu JiPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2021)
The combination of TMB-H and 19q12 + can serve as an early indicator of response to NACT. Superior to traditional clinical indicators, TMB-H is a robust and easily accessible candidate biomarker associated with better DFS, and can be evaluated at the time of diagnosis.